Female Fat Loss Stack

Semaglutide works primarily through appetite suppression and gastric emptying delay, mimicking the incretin hormone GLP-1. Research demonstrates significant weight reductions of 15-20% in clinical trials, with users reporting dramatically reduced food cravings and improved satiety signals. The peptide also influences reward pathways in the brain, reducing the appeal of high-calorie foods.

AOD-9604 complements semaglutide through a different mechanism entirely. This modified fragment of human growth hormone specifically targets adipose tissue, stimulating lipolysis (fat breakdown) whilst inhibiting lipogenesis (fat storage). Early studies suggest AOD-9604 may be particularly effective on visceral fat and stubborn subcutaneous deposits common in women's thighs, hips, and lower abdomen.

The synergy lies in addressing both energy intake and expenditure simultaneously. Whilst semaglutide creates a caloric deficit through reduced appetite, AOD-9604 ensures the body preferentially burns stored fat for fuel. This combination may help preserve lean muscle mass during weight loss, a crucial factor for maintaining metabolic rate. Users often report more consistent energy levels compared to traditional calorie restriction alone, as the body becomes more efficient at utilising fat stores.

Semaglutide Protocol: Begin with 0.25mg weekly, administered subcutaneously in the abdomen or thigh. Increase by 0.25mg every 4 weeks until reaching maintenance dose of 1.0-2.4mg weekly, depending on tolerance and results. Inject the same day each week, preferably before your lowest-activity day to manage potential nausea.

AOD-9604 Protocol: Administer 300mcg daily, preferably upon waking on an empty stomach. Inject subcutaneously in areas with higher fat concentrations (lower abdomen, thighs). Wait 20-30 minutes before eating to optimise absorption. Some users prefer splitting the dose: 150mcg morning and 150mcg pre-workout.

Reconstitution and Storage: Both peptides require proper reconstitution with bacteriostatic water. Consult our reconstitution guide for detailed mixing instructions. Store reconstituted semaglutide refrigerated for up to 28 days; AOD-9604 remains stable for 14 days refrigerated.

Cycle Length: Semaglutide can be used continuously with medical supervision, typically 3-6 month cycles. AOD-9604 cycles are typically 12-16 weeks, followed by 4-week breaks to maintain receptor sensitivity.

Injection Timing: Rotate injection sites to prevent lipodystrophy. Never inject both peptides in the same location simultaneously. Consider using our cost calculator to budget for supplies.

Weeks 1-2: Initial appetite suppression becomes noticeable with semaglutide, though some users experience mild nausea. AOD-9604 effects aren't yet visible, but fat mobilisation begins at the cellular level. Expect 0.5-1kg loss, primarily water weight.

Weeks 3-4: Appetite control stabilises, cravings significantly reduce. Energy levels may fluctuate as the body adapts. Weight loss accelerates to 0.5-1kg weekly. Measurements begin showing subtle changes in waist circumference.

Month 2: Consistent weekly weight loss of 0.75-1.25kg. Stubborn fat areas begin responding to AOD-9604. Clothing fits noticeably looser. Energy stabilises and often improves as metabolic flexibility increases.

Month 3: Total weight loss typically ranges 8-15kg depending on starting weight and adherence. Body composition improvements become obvious—reduced waist-to-hip ratio, visible muscle definition. Sleep quality and mood often improve alongside physical changes.

Common Side Effects: Semaglutide frequently causes initial nausea, particularly during dose escalation. Other reported effects include constipation, headaches, and fatigue. These typically subside within 2-3 weeks as the body adapts.

AOD-9604 is generally well-tolerated, with mild injection site reactions being the most common complaint. Some users report slight fatigue during the first week.

Contraindications: Avoid this stack if pregnant, breastfeeding, or planning pregnancy. Those with eating disorders, severe gastroparesis, or personal/family history of medullary thyroid carcinoma should not use semaglutide. Diabetics require careful blood glucose monitoring.

UK Legal Considerations: Both peptides exist in a legal grey area for personal use in the UK. Review our guide on UK peptide legality before purchasing. Only source from reputable suppliers with third-party testing certificates.